LEADER 03624nam 22004815 450 001 9910731468803321 005 20230610113711.0 010 $a3-031-28536-0 024 7 $a10.1007/978-3-031-28536-3 035 $a(MiAaPQ)EBC30591726 035 $a(Au-PeEL)EBL30591726 035 $a(DE-He213)978-3-031-28536-3 035 $a(PPN)272261653 035 $a(CKB)26895857000041 035 $a(EXLCZ)9926895857000041 100 $a20230610d2023 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDiabetes and COVID-19 $eConsiderations and Clinical Management /$fedited by Alyson K. Myers 205 $a1st ed. 2023. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2023. 215 $a1 online resource (225 pages) 225 1 $aContemporary Endocrinology,$x2523-3793 311 08$aPrint version: Myers, Alyson K. Diabetes and COVID-19 Cham : Springer International Publishing AG,c2023 9783031285356 327 $aCOVID-19: epidemiology, etiology, clinical manifestations, diagnosis, therapeutic options, and prevention -- Pathophysiology: How COVID-19 Impacts the Pancreas and Peripheral Insulin Resistance -- Risk of COVID-19 in Persons with Diabetes -- Pathophysiology of Lung Dysfunction in Diabetes -- Diabetic kidney disease and COVID-19 -- The Impact of COVID-19 on Diabetic Foot Ulcers -- Co-morbid obesity and its impact on diabetes and COVID-19 -- Overview of Inpatient Mgt of Diabetes and COVID 19 -- Management of critically ill persons with COVID-19 and diabetes -- Managing Outpatient Diabetes in Persons with COVID-19 and Diabetes -- The Use of Diabetes Technology In Persons With Diabetes and Coronavirus 2019 (COVID-19) -- COVID-19 Vaccination in Persons with Diabetes -- COVID-19 Vaccination in Persons with Diabetes -- Long-haul COVID Symptoms in Person with Diabetes. 330 $aManaging COVID-19 alone can be a difficult in many cases, but for persons with pre-existing conditions such as diabetes the challenge can be all the greater, and specific considerations need to be taken when prescribing treatment to manage them. This book is a culmination of scientific work driven by personal conviction to enhance the care provided to the vulnerable populations COVID-19 patients with diabetes. It spans topics from the epidemiology and predictors of complications and increased mortality in COVID-19, to in-depth discussion of the pathophysiology of the disease. Pathophysiology of COVID-19 is addressed comprehensively as common soil pathogenetic pathways, and by organ system such as the lung, the kidney and most pertinently for diabetes, the diabetic foot ulcers and diabetes co-morbidities. A multi-disciplinary approach was needed to manage these complex patients; thus, the authors represent a variety of disciplines including pharmacology, endocrinology, nephrology, infectious diseases, podiatry, vascular surgery, pulmonary/critical care, and general medicine. Written by experts in the field, Diabetes and COVID-19: Considerations and Clinical Management is a blueprint for treatment of patients with both conditions. . 410 0$aContemporary Endocrinology,$x2523-3793 606 $aEndocrinology 606 $aEndocrinology 615 0$aEndocrinology. 615 14$aEndocrinology. 676 $a616.24144 700 $aMyers$b Alyson K$01369169 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910731468803321 996 $aDiabetes and COVID-19$93395247 997 $aUNINA